Decapeptyl Depot - Triptorelin Injection

Decapeptyl Depot - Triptorelin Injection Specification

Salt Composition
Triptorelin (as Triptorelin Acetate) 3.75 mg per vial

Indication
Prostate cancer, Endometriosis, Uterine fibroids, Precocious puberty, Assisted reproductive technologies

Dosage Form
Lyophilized powder for Suspension for Injection (Depot Formulation)

Enzyme Types
Not applicable (Peptide analogue)

Feature
3.75 mg monthly depot, sustained-release formulation

Ingredients
Triptorelin acetate, excipients (mannitol, carmellose sodium, polysorbate 80, D,L-lactic and glycolic acids copolymer)

Application
Parenteral (intramuscular injection)

Physical Color/Texture
White to off-white lyophilized powder

Fermentation Smell
Odorless

Storage Instructions
Store below 25C (77F), protect from light, do not freeze

Shelf Life
36 months from date of manufacture

Contraindications
Known hypersensitivity to Triptorelin, pregnancy, lactation

Release Type
Prolonged-release (Depot)

Route of Administration
Intramuscular injection

ATC Code
L02AE04

Reconstitution
Reconstitute with supplied sterile solvent before use

Special Storage
After reconstitution, use immediately or within a specified time per manufacturer's instructions

Prescription
Prescription only

Marketed By
Ferring Pharmaceuticals

Compatibility
Should not be mixed with other medicinal products

Latex-Free
Yes, vial and packaging are latex-free

Patient Population
Adults and pediatric patients as indicated

Packaging
Single dose vial with sterile solvent for reconstitution

About Decapeptyl Depot - Triptorelin Injection

Select Decapeptyl Depot Triptorelin Injection for remarkable efficacy in hormone-dependent indications such as prostate cancer, endometriosis, uterine fibroids, precocious puberty, and assisted reproductive technologies. This outstanding monthly depot formulation, containing 3.75 mg Triptorelin (as acetate) per vial, is provided in an unmatchable single-dose vial with sterile solvent and is latex-free. Perfect for intramuscular administration in both adults and pediatric patients as indicated, it offers sustained release for prolonged effect. Last chance for purchase as prescribed; rely on Ferring Pharmaceuticals for trusted quality. Reconstitute just prior to use and never mix with other medicinal products.

Optimized Usage and Outstanding Benefits

Decapeptyl Depot Triptorelin Injection is used as a prolonged-release depot formulation, administered intramuscularly to optimize treatment in indicated diseases. Its advantage lies in sustained-release action, reducing frequency of dosing and enhancing patient compliance. Recommended for both adults and pediatric patients, it is used as a dependable therapy for hormone-related disorders. The latex-free packaging further assures safety and suitability for a wide patient population.

Export Market, Certifications, Sample Policy

Decapeptyl Depot Triptorelin Injection is exported to main markets including Asia, Africa, and Europe. It carries all necessary certifications to guarantee quality and regulatory compliance globally. Expenditure includes freight, packing & dispatch costs according to market destination. Sample policy is available upon request for authorized dealers, distributors, and traders, enabling comprehensive evaluation prior to larger consignments.

FAQs of Decapeptyl Depot - Triptorelin Injection:

Q: How should Decapeptyl Depot Triptorelin Injection be administered?

A: Decapeptyl Depot should be administered via intramuscular injection after reconstitution with the supplied sterile solvent, strictly as per the prescription and medical guidance.

Q: What precautions must be followed during the reconstitution process?

A: Reconstitute the lyophilized powder with the provided sterile solvent immediately before use, and do not mix with other medicinal products. Follow manufacturers instructions for safe and effective reconstitution.

Q: When is Decapeptyl Depot indicated for use?

A: Decapeptyl Depot is indicated for the treatment of prostate cancer, endometriosis, uterine fibroids, precocious puberty, and in assisted reproductive technologies, as determined by the prescribing physician.

Q: Where should Decapeptyl Depot be stored prior to use?

A: Prior to use, Decapeptyl Depot should be stored below 25C (77F), protected from light, and should not be frozen to maintain its efficacy and stability.

Q: What is the main benefit of using the prolonged-release (Depot) formulation?

A: The depot formulation provides sustained Triptorelin release, reducing dosing frequency, ensuring consistent therapeutic levels, and improving patient adherence over monthly treatment cycles.